New ZEISS Integrated Intraoperative OCT Provides Surgeons Unprecedented Views of Transparent Ocular Structures in a Surgical ...
December 22 2014 - 12:00PM
Business Wire
The medical technology company ZEISS was the first to
introduce a surgical microscope and the first to commercially offer
OCT for ophthalmic applications. By merging two gold standards into
one system, ZEISS has created another first: a surgical microscope
with integrated intraoperative OCT, the OPMI LUMERA® 700 and
RESCAN™ 700. Now available in the Unites States, RESCAN 700
provides ophthalmic surgeons the highest-quality intraoperative OCT
visualization of the eye without any interruption of
surgery.
The U.S. Food and Drug Administration has cleared RESCAN 700 for
sale in the United States, bringing to U.S. ophthalmologists an
emerging technology that aims to overcome the trouble surgeons may
have in seeing certain anatomical details during eye surgery.
(Photo: Business Wire)
High-definition OCT images appear directly in the LUMERA 700
microscope eyepiece, adding a real-time third dimension to the
visualization capabilities. Surgeons are provided unprecedented
views below the surface of the surgical field – enabling them to
see more, even transparent structures in the anterior and posterior
segment of the eye.
“Intraoperative OCT allows me to see things I could not see
otherwise,” said Justis P. Ehlers, MD, of Cleveland, Ohio, who has
been using RESCAN 700 on an investigational basis for nine months.
“I use intraoperative OCT in most of my surgeries. We have found
that real-time OCT feedback during surgery can improve our
understanding of anatomy and impact surgical decision-making,
particularly in membrane peeling cases and complex detachments --
for example, proliferative diabetic retinopathy and proliferative
vitreoretinopathy.”
ZEISS RESCAN 700 helps surgeons to concentrate more on the
surgical procedure, as the necessary structural information known
from pre-operative OCTs is available all the time intraoperatively.
Additionally, the continuous OCT scanning supports achieving better
patient outcomes because the surgeon can monitor progress and
verify results during the procedure.
“One of the great features of the RESCAN 700 is the foot pedal
control of the OCT beam – I can rapidly place it right where I need
it during the surgery,” said Dr. Ehlers, who has been the lead
investigator for a prospective study with more than 200 cases
examining microscope-integrated OCT and ophthalmic surgery. “And
the Z-tracking feature enables improved stability of the OCT image
during surgery-induced motion.”
OCT scans can also be stored and recalled for review. That way
the new device enables better decision-making during surgery. “As a
surgeon, I appreciate the confirmation of my surgical objectives
that intraoperative OCT provides,” Dr. Ehlers said. “I receive
guidance for where it’s optimal to start surgical maneuvers, and
then subsequent feedback on whether I have accomplished the
surgical objectives.”
RESCAN 700 is useful for various surgeries in the anterior and
posterior segment of the eye with a broad range of potential
applications. “We are happy that now U.S. surgeons can also benefit
from this new visualization technology and its potential to help
them improve patient outcomes,” said Dr. Ludwin Monz, President and
CEO of Carl Zeiss Meditec AG. “The merging of two of our gold
standards into one system creates vast possibilities for changing
ophthalmic surgery and expanding the capabilities of surgeons,
especially for retina and cornea procedures.”
RESCAN 700 was recently recognized as one of the top 15 medical
innovations in the “2014 Innovation Awards,” published by The
Ophthalmologist.
www.meditec.zeiss.com/press
Carl Zeiss Meditec AG
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on
TecDAX of the German stock exchange, is one of the world’s leading
medical technology companies. The company supplies innovative
technologies and application-oriented solutions designed to help
doctors improve the quality of life of their patients. It provides
complete packages of solutions for the diagnosis and treatment of
eye diseases, including implants and consumable materials. The
company creates innovative visualization solutions in the field of
microsurgery. The medical technology portfolio of Carl Zeiss
Meditec is rounded off by promising, future-oriented technologies
such as intraoperative radiotherapy. In financial year 2012/2013
(ended 30 September) the Group's more than 2,500 employees
generated revenue of € 906 million. The head office of Carl Zeiss
Meditec is in Jena, Germany.
The company has subsidiaries in Germany and abroad; more than 50
percent of its employees are based in the USA, Japan, Spain and
France. The Center for Research and Development (CARIn) in
Bangalore, India and the Carl Zeiss Innovations Center for Research
and Development in Shanghai, China, strengthen the Company's
presence in these rapidly developing economies. Around 35 percent
of Carl Zeiss Meditec shares are in free float. The remaining 65
percent are held by Carl Zeiss AG, one of the world’s leading
groups in the optical and optoelectronic industries.
For more than 160 years, Carl Zeiss has been contributing to the
progress of technology on the markets for Industrial Solutions,
Research Solutions, Medical Technology and Consumer Optics,
improving the quality of life for many people. Carl Zeiss AG,
Oberkochen, is wholly owned by the Carl Zeiss Foundation.
For more information visit our website at: www.meditec.zeiss.com
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20141222005141/en/
Press contact:Carl Zeiss Meditec, Inc.Bill Taggart, +1
925-493-9251Group CommunicationsDublin,
Californiawilliam.taggart@zeiss.comorCarl Zeiss Meditec AGJann
Gerrit Ohlendorf, +49 (0) 3641 220-331Group
Communicationspress.meditec@zeiss.comorContact for investors:Carl
Zeiss Meditec AGSebastian Frericks, +49 (0) 3641 220-116Investor
Relationsinvestors.meditec@zeiss.com